Skip to main content
. 2021 Apr 10;2(4):326–337. doi: 10.1158/2643-3230.BCD-20-0229

Figure 3.

Figure 3.

Treatment outcome based on leukemia cell subtype and MRD levels in bone marrow on day 15 (A) and day 42 (B). See Tables 2 and 3 for additional data. CRR, cumulative risk of any relapse; EFS, event-free survival; HD, hyperdiploidy; OS, overall survival.